[go: up one dir, main page]

WO2009005688A3 - Activating mutations in notch-1 - Google Patents

Activating mutations in notch-1 Download PDF

Info

Publication number
WO2009005688A3
WO2009005688A3 PCT/US2008/007958 US2008007958W WO2009005688A3 WO 2009005688 A3 WO2009005688 A3 WO 2009005688A3 US 2008007958 W US2008007958 W US 2008007958W WO 2009005688 A3 WO2009005688 A3 WO 2009005688A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
notch
effects
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/007958
Other languages
French (fr)
Other versions
WO2009005688A2 (en
Inventor
Aldolfo A Ferrando
Maria Luisa Sulis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of WO2009005688A2 publication Critical patent/WO2009005688A2/en
Publication of WO2009005688A3 publication Critical patent/WO2009005688A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to certain methods and compositions for diagnosing, preventing, treating, and/or ameliorating the effects of various conditions in a mammal, such as T-cell lymphoblastic leukemia and lymphoma. The present invention also relates, inter alia, to methods of determining whether reducing or blocking NOTCH 1 activation will be effective to treat, prevent, or ameliorate the effects of a cancer in a patient. Such methods may include determining if the patient harbors one or more mutations in exon 28 or intron 27 of the NOTCH1 gene.
PCT/US2008/007958 2007-06-29 2008-06-26 Activating mutations in notch-1 Ceased WO2009005688A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93798107P 2007-06-29 2007-06-29
US60/937,981 2007-06-29
US6580408P 2008-02-15 2008-02-15
US61/065,804 2008-02-15

Publications (2)

Publication Number Publication Date
WO2009005688A2 WO2009005688A2 (en) 2009-01-08
WO2009005688A3 true WO2009005688A3 (en) 2009-04-16

Family

ID=40226718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/007958 Ceased WO2009005688A2 (en) 2007-06-29 2008-06-26 Activating mutations in notch-1

Country Status (1)

Country Link
WO (1) WO2009005688A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11370823B2 (en) 2014-10-29 2022-06-28 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0215182A (en) 2001-12-20 2004-10-19 Bristol Myers Squibb Co (Alpha) - (n-sulfonamido) acetamide derivatives as (beta) -amyloid inhibitors
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2014039908A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
WO2019148067A1 (en) 2018-01-26 2019-08-01 Massachusetts Eye And Ear Infirmary Treatment of hearing loss

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703221B1 (en) * 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
US20070077245A1 (en) * 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
US20070083334A1 (en) * 2001-09-14 2007-04-12 Compugen Ltd. Methods and systems for annotating biomolecular sequences

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703221B1 (en) * 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
US20070083334A1 (en) * 2001-09-14 2007-04-12 Compugen Ltd. Methods and systems for annotating biomolecular sequences
US20070077245A1 (en) * 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] MANN ET AL: "Complete Human NOTCH 1 (hN1) cDNA Sequence", Database accession no. AF308602 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11370823B2 (en) 2014-10-29 2022-06-28 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear

Also Published As

Publication number Publication date
WO2009005688A2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
WO2009005688A3 (en) Activating mutations in notch-1
MX366119B (en) Methods for treating conditions associated with masp-2 dependent complement activation.
MX2009011366A (en) Methods and compositions for treating and monitoring treatment of il-13-associated disorders.
WO2009064444A9 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2005123128A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2008021210A3 (en) Methods and compositions for the treatment of neurodegenerative disorders
UA95310C2 (en) Composition containing chkl inhibitor and cyclodextrin for the treatment of cancer
EP3750560A3 (en) Combination therapies and uses for treatment of demyelinating disorders
PL1682126T3 (en) Substituted benzazoles and use thereof as inhibitors of raf kinase
WO2007053573A3 (en) Treatment of cancer with sorafenib
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
WO2005018677A3 (en) Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
PL1902141T3 (en) Adamts13-comprising compositions having thrombolytic activity
IL201284A (en) Pyridopyrimidinone inhibitor of pi3k alpha for use in combination with one or more chemotherapeutic agents selected from taxol, rapamycin, carboplatin and erlotinib for the treatment of cancer
WO2004087075A3 (en) Compositions and methods for treating cancer
SG156641A1 (en) Compounds for nonsense suppression, and methods for their use
WO2009036188A3 (en) Insulin-like growth factor binding protein 7 for treatment of cancer
SG150559A1 (en) Antineoplastic combinations of cci-779 and rituximab
WO2005054503A3 (en) Biomarkers for graft rejection
SI1603941T1 (en) Inhibitors of extracellular hsp90
NZ544719A (en) Combination of mGluR2 antagonist and aChE inhibitor for treatment of acute and/or chronic neurological disorders
WO2004009609A3 (en) Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
WO2005118869A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2003059254A3 (en) Prevention and treatment of atherosclerosis and restenosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08779793

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08779793

Country of ref document: EP

Kind code of ref document: A2